Protons against cancer: New research beamline for innovative radiotherapies
Prof. Dr Judith Reindl and PhD student Aikaterini Rousseti (from left to right) from the University of the Bundeswehr Munich present the experimental station for biological samples which is installed at the new Minibee beamline at HZB. © Kevin Fuchs / HZB
Magnetic quadrupoles focus the proton beam in front of the experiment platform. © Kevin Fuchs / HZB
Together with the University of the Bundeswehr Munich, the HZB has set up a new beamline for preclinical research. It will enable experiments on biological samples on innovative radiation therapies with protons.
The proton accelerator at the Helmholtz-Zentrum Berlin (HZB) has been used for about 25 years to combat certain types of eye tumours. So far, over 4800 people have benefited from proton eye tumour therapy, which is carried out in collaboration with Charité – Universitätsmedizin Berlin.
Now, the proton accelerator at HZB also offers the option of conducting preclinical research: A mini-beamline for preclinical experiments (Minibee) has been set up for this purpose together with the University of the Bundeswehr in Munich. The HZB's Proton Therapy Department has built the beam guidance and control system for the minibeams. The University of the Bundeswehr in Munich, with Prof. Judith Reindl from the Institute of Applied Physics and Measurement Technology and the Section of Biomedical Radiation Physics, installed a platform for image-guided irradiation of biological samples. This will enable joint experiments on radiobiology and innovative radiation therapy in the future.
‘At Minibee, we can use medical research to investigate how changes in parameters and settings of the proton beam affect the treatment,’ says Judith Reindl. Among other things, Minibee is designed to generate ultrashort proton flashes (FLASH therapy) or needle-fine radiation (beamlets). ‘Our aim is to develop new methods that effectively destroy tumours while providing even better protection for healthy tissue,’ says Prof. Dr. Andrea Denker, head of the Department of Proton Therapy at HZB.
arö
https://www.helmholtz-berlin.de/pubbin/news_seite?nid=28606;sprache=en
- Copy link
-
Joint power instead of duplicate structures:
Berlin’s research community is further advancing its research excellence by establishing a high-performance, cross-institutional infrastructure for data and AI. With a joint agreement signed on 18 September 2026, the Berlin University Alliance (BUA), the Helmholtz-Zentrum Berlin (HZB) and the Zuse Institute Berlin (ZIB) are paving the way for a joint data science and AI centre in Berlin-Dahlem and Adlershof.
-
New technique could make MRI more precise
A team of researchers at the University of Stuttgart and HZB has developed a new method that could make MRI even more precise by eliminating “dead time,” a key limiting factor in the measurement process, thereby enabling the detection of signals that are lost using conventional methods. This method opens up new possibilities for medical diagnostics and non-destructive materials testing. The research team presents the new approach in Science Advances.
-
BESSY II: High-resolution insights into individual biomolecules and catalysts
Very small biological samples and even individual biomolecules can now be examined under near-physiological conditions with high confidence at the BESSY II infrared beamline with a newly validated and improved technique: The nanoscale infrared spectroscopy (s-SNOM) with ultra-thin silicon-based membranes. An international team demonstrated after an initial proof of concept, that high-resolution (a few tens of nanometres) nano-IR measurements reliably match expected far-field IR spectra in an aqueous environment. This methodological advance provides a solid foundation for studying biomaterials or observing catalytic processes in a liquid environment.